Therapeutic Potential of Polydatin Against Cancer Cachexia by Regulating the STAT3 Signaling Pathway.

Area of Science:

• Biochemistry
• Pharmacology
• Oncology

Background:

• Cancer cachexia is a severe wasting syndrome characterized by significant body weight and muscle mass loss in advanced cancer patients.
• Current treatments for cancer cachexia are limited, highlighting the need for novel therapeutic strategies.
• Understanding the underlying mechanisms of muscle atrophy is crucial for developing effective interventions.

Purpose of the Study:

• To evaluate the therapeutic potential of the natural compound polydatin in a preclinical model of cancer cachexia.
• To investigate the molecular mechanisms by which polydatin ameliorates muscle atrophy, focusing on the IL6/STAT3 signaling pathway.

Main Methods:

• In vivo studies using CT26-bearing mice to assess polydatin's effects on body weight, muscle mass, and inflammation.
• In vitro experiments with C2C12 myoblasts to analyze polydatin's impact on muscle atrophy induced by cancer-conditioned medium.
• Molecular docking simulations to predict the interaction between polydatin and key proteins in the IL6/STAT3 pathway.

Main Results:

• Polydatin treatment (100 mg/kg) significantly reversed body weight loss, muscle atrophy, and inflammation in cancer cachexia model mice.
• Polydatin administration attenuated muscle fiber shrinking, normalized the expression of E3 ubiquitin ligases (MuRF1, Atrogin-1), and reduced interleukin-6 levels.
• In vitro, polydatin ameliorated muscle atrophy and suppressed STAT3 phosphorylation in C2C12 myotubes.

Conclusions:

• Polydatin demonstrates significant therapeutic efficacy in attenuating muscle atrophy associated with cancer cachexia.
• The mechanism involves the inhibition of the STAT3 signaling pathway, suggesting polydatin as a promising candidate for cancer cachexia drug development.